The partnership validates ARCT-032's pipeline potential and provides a credible path to Phase 3, but the stock remains binary on Phase 2 readout. Watch for Phase 2 results before expecting Phase 3 initiation — that data release is the next major catalyst. The $40M in contributed manufacturing services also reduces near-term cash burn, extending runway.
Price Chart
Executive Summary
Arcturus Therapeutics entered into a strategic collaboration with Thermo Fisher Scientific to provide CRO and CDMO services for Phase 3 development of ARCT-032, its mRNA therapy for cystic fibrosis. Per the agreement, Thermo Fisher will contribute up to $40 million in clinical manufacturing services, and Arcturus will engage PPD for up to $40 million in CRO services, with Thermo Fisher receiving exclusive commercial manufacturing rights upon regulatory approval. This partnership de-risks a key pipeline catalyst but offers no near-term revenue; Phase 2 data is awaited before Phase 3 can begin.
Key Financial Metrics
Key Facts
- Thermo Fisher to contribute up to $40M in clinical manufacturing services for ARCT-032 (mRNA cystic fibrosis therapy).
- Arcturus to engage PPD (Thermo Fisher CRO) for up to $40M in clinical research services.
- Upon regulatory approval, Thermo Fisher receives exclusive commercial manufacturing rights for ARCT-032.
- Agreement has a 5-year initial term with automatic one-year renewals unless terminated with 90 days' notice.
- If Phase 2 yields positive results, Arcturus expects to conduct Phase 3 through Thermo Fisher's PPD clinical research business.
- Project Agreement covers technical transfer, engineering batches, clinical trial material manufacture, process performance qualification batches, drug product fill & finish, release, and stability studies.
- No financial terms disclosed for the commercial supply agreement beyond the $40M manufacturing contribution and $40M CRO services engagement.
Financial Impact
Thermo Fisher contributing $40M in manufacturing services; Arcturus committing up to $40M in CRO services. No milestone payments or royalties disclosed.
Risk Factors
- ARCT-032 Phase 2 results may fail to support Phase 3 initiation, rendering the agreement non-material for the stock.
- No definitive commercial supply agreement yet — terms to be negotiated in good faith if regulatory approval is achieved.
- Exclusive commercial manufacturing rights could limit Arcturus' flexibility in pricing or alternative supply if commercial success materializes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193805-26-000910 |
| Document: e665618_ex99-1.htm | 0001193805-26-000910 |
| Document: 0001193805-26-000910-index-headers.html | 0001193805-26-000910 |
| Document: 0001193805-26-000910-index.html | 0001193805-26-000910 |
| Document: 0001193805-26-000910.txt | 0001193805-26-000910 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | SC 13G/A | $12.77 | awaiting T+20 | — | $9.84 (−22.91%) |
Sep 28, 2026 29d ago | Court Ruling | $13.70 | awaiting T+20 | — | $9.84 (−28.18%) |
Aug 25, 2026 8w ago | 8-K | $15.44 $14.69 | ▼ −4.86% | ▼ −6.10% | $9.84 (−36.27%) |
Aug 15, 2026 10w ago | Institutional Cluster | $8.14 $15.84 | ▲ +94.59% | ▲ +96.57% | $9.84 (+20.88%) |
Jul 2, 2026 16w ago | 8-K | $7.28 $5.92 | ▼ −18.68% | ▼ −18.27% | $9.84 (+35.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers